AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Oxford Biomedica PLC

Declaration of Voting Results & Voting Rights Announcements Jun 30, 2014

5190_rns_2014-06-30_99ea0ec5-be67-49ab-b300-613ddca8bd35.html

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7488K

Oxford Biomedica PLC

30 June 2014

FOR IMMEDIATE RELEASE 30 June 2014

OXFORD BIOMEDICA PLC

Total Voting Rights Update

In accordance with the FCA's Disclosure and Transparency Rules, Oxford BioMedica plc (LSE:OXB) confirms that the Company's issued share capital consists of 2,494,584,919 ordinary shares of 1p each, all with voting rights.  No shares are held in treasury.

This figure may be used by shareholders as the denominator for the calculation by which they will determine whether they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

For further information, please contact:
Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Media Enquiries:

Mary-Jane Elliott/Emma Thompson/Matthew Neal

Consilium Strategic Communications
Tel: +44 (0)20 3709 5700

Notes to editors

Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVRGCGDLGUDBGSR

Talk to a Data Expert

Have a question? We'll get back to you promptly.